Ischemic optic neuropathy associated with low-dose interferon alfa: Report of two cases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 1, 2009, Pages 86-87

  Rodney, Alan J ^a   Gombos, Dan S ^a   Pagliaro, Lance C ^a   Tannir, Nizar M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Interferon alfa; Ischemic optic neuropathy; Renal cell carcinoma

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; BRIMONIDINE; PREDNISONE; STEROID;

AFFERENT PUPILLARY DEFECT; AGED; ARTICLE; CASE REPORT; CENTRAL SCOTOMA; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INTRAOCULAR HEMORRHAGE; ISCHEMIC OPTIC NEUROPATHY; KIDNEY CARCINOMA; LABORATORY TEST; LOW DRUG DOSE; MALE; OPHTHALMOSCOPY; PAPILLEDEMA; RECURRENT CANCER; SCOTOMA; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; BONE TUMOR; CHEMICALLY INDUCED DISORDER; KIDNEY TUMOR; LUNG TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; STERNUM;

AGED; BONE NEOPLASMS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; OPTIC NEUROPATHY, ISCHEMIC; PROGNOSIS; STERNUM; TREATMENT OUTCOME;

EID: 60549087755     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000227526.96319.50     Document Type: Article

References (4)

1. Hayasaka S, Nagaki Y, Matsumoto M, et al. Interferon associated retinopathy. Br J Ophthalmol. 1998;82:323-325.
2. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science. 1980;208:516-518.
3. Kirkwood JM, Richards T, Zarour HM, et al. Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002;95:1101-1112.
4. Hayreh SS, Zimmerman MB, Hayreh Zimmerman MB, et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603-624.